July 13, 2017 07:58 AM EDT

Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs

Zachary Brennan

Senior Editor

In a moment of bipartisanship, the US House of Representatives on Wednesday passed a bill via voice vote to reauthorize the prescription drug, generic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

CagriSema’s weight loss data disappointed. What does Novo do next?

Fac­ing a crit­i­cal Au­gust dead­line, House pass­es bill to reau­tho­rize FDA user fee pro­grams

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Facing a critical August deadline, House passes bill to reauthorize FDA user fee programs

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

FDA approves subcutaneous version of Bristol Myers' Opdivo

CagriSema’s weight loss data disappointed. What does Novo do next?